Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease.

Remadevi V, Jamadar A, Varghese MM, Yang H, Gunewardena S, Wallace DP, Rao R

Open source

DOI
10.1172/jci.insight.207552
Published
2026 Sep 22
Container
JCI insight
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1172/jci.insight.207552,
  title = {Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease.},
  author = {Remadevi V and Jamadar A and Varghese MM and Yang H and Gunewardena S and Wallace DP and Rao R},
  year = {2026},
  journal = {JCI insight},
  doi = {10.1172/jci.insight.207552},
  url = {https://doi.org/10.1172/jci.insight.207552}
}

RIS

TY  - JOUR
TI  - Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease.
AU  - Remadevi V
AU  - Jamadar A
AU  - Varghese MM
AU  - Yang H
AU  - Gunewardena S
AU  - Wallace DP
AU  - Rao R
PY  - 2026
JO  - JCI insight
DO  - 10.1172/jci.insight.207552
UR  - https://doi.org/10.1172/jci.insight.207552
ER  - 

APA

V, R., A, J., MM, V., H, Y., S, G., DP, W., & R, R. (2026). Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease.. JCI insight. https://doi.org/10.1172/jci.insight.207552

Source records